Atherosclerosis Clinical Trial
Official title:
Double-blind Parallel Placebo-controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients With Stable Angina Pectoris Undergoing a Percutaneous Coronary Intervention
Molsidomine used as an add-on treatment on standard care therapy should be superior to
placebo used also as an add-on treatment on standard care therapy on improving the
endothelial function (endothelium score measured by reactive hyperemia - peripheral arterial
tonometry [RH-PAT]) after 12 months of treatment in patients with stable angina patients and
undergoing elective percutaneous coronary intervention.
The study will be double-blind, parallel-group, randomised, multicentre, sequential,
placebo-controlled study.
The device used to determine RH-PAT will be EndoPAT. Duration of the treatment = one year.
A Data Steering Committee (DSC) will blindly assess the recruitment rate, the variability of
RH-PAT within and between centres, and the safety on a regular basis.
Sequential approach:
- In the first phase (Phase A) of the study, 180 patients will be enrolled in order to
get at least 50 completers after 12 months of treatment. A statistical evaluation of
the primary endpoint will be done by an Independent Biostatistician after approximately
50 patients have completed the study in accordance with the protocol.
- The results will be examined by an Independent Data Monitoring Committee (IDMC)which
will assess the results and advise the sponsor as to:
1. Continue the study if the primary objective has not been achieved but the
difference between the two groups is at least 10% (difference considered
clinically significant). In this case, the sample size will be recalculated by the
Independent Biostatistician taking into account actual difference and variability.
The total number of patients to be enrolled in addition in Phase B will be
calculated with precision. Depending on IDMC recommendations, the number of
investigating centres will be increased or not for Phase B. If the right number of
patients has already been enrolled, Phase B will not start. The study will stop
when all enrolled patients have completed the one-year treatment period.
2. Terminate the study, if the difference between the two groups is less than 10%.
3. Consider the study as completed if the primary endpoint has been achieved.
Treatment allocation: Balanced allocation between molsidomine and placebo (1:1) with a
stratification for consumption of statins, for the type of stent (drug-eluting stent or
bare-metal) and for consumption of angiotensin-converting enzyme inhibitors (ACEIs).
Data collection: Electronic Case Report Form (eCRF).
Duration of study: A minimum of 30 months (16 months for inclusion and 14 months for the
study) for Phase A.
Number of investigational centres:
- Up to 10 centres for Phase A
- To be determined for Phase B based on Phase A.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05052918 -
The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes
|
N/A | |
Recruiting |
NCT04511234 -
Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
|
N/A | |
Completed |
NCT05906797 -
Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis.
|
N/A | |
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Suspended |
NCT02932176 -
Machine Learning for Handheld Vascular Studies
|
||
Recruiting |
NCT05158257 -
Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity
|
N/A | |
Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
Completed |
NCT03697382 -
Effect of Daily Steps on Fat Metabolism
|
N/A | |
Recruiting |
NCT06230406 -
T-Mem GEne in Atherosclerosis
|
||
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT00382564 -
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
|
N/A | |
Recruiting |
NCT02894931 -
Effects of Dietary Interventions on Serum and Macrophage Atherogenicity
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|
||
Completed |
NCT02224339 -
New Technologies to Determine Carotid Plaque Vulnerability
|
||
Completed |
NCT03393377 -
Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination
|
N/A | |
Completed |
NCT02268513 -
Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
|
||
Completed |
NCT02116829 -
Is There Room for Butter in a Healthy Diet?
|
N/A | |
Not yet recruiting |
NCT01923012 -
Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis
|
Phase 2 |